

## Special Issue

# Recent Scientific Development of Poliovirus Vaccines

### Message from the Guest Editor

In 1988, the World Health Assembly established the Global Polio Eradication Initiative, an international effort to terminate all transmissions of wild poliovirus by 2000. Eradication requires (1) effective means to prevent poliovirus infections and/or transmissions and (2) effective surveillance programs to identify poliovirus infections and evaluate the effectiveness of interventions in individuals and/or in unidentified persons within populations. Many stakeholders have been involved in developing and improving the two main types of vaccines in current use, inactivated (IPV) and live attenuated (OPV) vaccines. However, the ideal polio vaccine, “effective in any outbreak scenario, protect[ing] all vaccinees with one dose, spread[ing] to and protect the unvaccinated population, and have[ing] no detrimental effect” is yet to be developed. This Special Issue of *Vaccines* focuses on recent scientific advancements achieved from the development and field testing of improved, more genetically stable, oral polio vaccines as well as from current research on alternative vaccines and vaccination strategies.

### Guest Editor

Prof. Dr. Lester M. Shulman

1. Retired, Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
2. Laboratory of Environmental Virology, Retired, Central Virology Laboratory, Public Health Services Israel Ministry of Health Sheba Medical Center, Tel Hashomer 52621, Israel

### Deadline for manuscript submissions

closed (31 January 2026)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/197335](https://mdpi.com/si/197335)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).